Researchers conducted a study to determine the effect of a national human papillomavirus (HPV) immunization program on the incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia among young women in England.
CDC Director Rochelle P. Walensky, MD, MPH endorsed the ACIP’s recommendation.
The panel reviewed safety and efficacy data from a phase 2/3 study that included 2268 participants who received a 2-dose regimen of 10mcg administered 21 days apart.
The update applies to patients who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown.
The expanded approval was based on data from a phase 3 study that compared Flucelvax Quadrivalent to a US-licensed comparator quadrivalent influenza vaccine.
Routine annual influenza vaccination is recommended for all patients 6 months of age and older who have no medical contraindications.
A single booster dose may be administered to individuals 65 years and older and those at high risk of severe disease or exposure to SARS-CoV-2.
Comirnaty is indicated for individuals 16 years of age and older, however the vaccine remains available to those aged 12 years and older under the EUA.
Americans will be able to start getting a booster of the mRNA COVID-19 vaccine starting September 20, 2021.
Push will include enlisting pediatricians to make COVID-19 vaccination part of back-to-school sports physicals.
